

# Results of the 1<sup>st</sup> Half-Year 2013/14

Investor Call  
Mannheim, 30<sup>th</sup> September 2013

PHOENIX group

Reimund Pohl  
CEO

Helmut Fischer  
CFO



© 2013 PHOENIX Pharmahandel GmbH & Co KG

This document has been prepared by PHOENIX Pharmahandel GmbH & Co KG (the “Company” and, together with its subsidiaries and affiliates, “PHOENIX”) solely in connection with the release of the results of the 1<sup>st</sup> half-year 2013/14 and is being presented solely for informational purposes. No representation or warranty, express or implied, is or will be made in relation to, and no responsibility is or will be accepted by the Company or any of its respective affiliates, advisors or representatives (together, the “Parties”) as to the accuracy or completeness of the information contained in this document, and nothing in this document shall be deemed to constitute such a representation or warranty. None of the Parties or their respective agents, directors, partners and employees accept any liability whatsoever (in negligence or otherwise) for any loss or damage howsoever arising from any use of this document or its contents or otherwise arising in connection therewith and no reliance should be placed on the information or statements made herein.

This document does not constitute or form part of and should not be construed as a recommendation, offer or invitation for the purchase or subscription of any securities of the Company or any subsidiary, and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

The information contained in this presentation has not been subject to any independent audit or review. A portion of the information contained in this document, including all market data and trend information, is based on estimates or expectations of the Company, and there can be no assurance that these estimates or expectations are or will prove to be accurate. In addition, past performance of PHOENIX is not indicative of future performance. The future performance of PHOENIX will depend on numerous factors which are subject to uncertainty.

Certain statements contained in this presentation that are not statements of historical fact, including, without limitation, any statements preceded by, followed by or including the words “targets”, “believes”, “expects”, “aims”, “intends”, “may”, “anticipates”, “would”, “could” or similar expressions or the negative thereof, constitute forward-looking statements, notwithstanding that such statements are not specifically identified. In addition, certain statements may be contained in press releases, and in oral and written statements made by or with the approval of the Company that are not statements of historical fact and constitute forward-looking statements. Examples of forward-looking statements include, but are not limited to: (i) statements about future financial and operating results; (ii) statements of strategic objectives, business prospects, future financial condition, budgets, projected levels of production, projected costs and projected levels of revenues and profits of the Company or its management; (iii) statements of future economic performance; and (iv) statements of assumptions underlying such statements.

Forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict and outside of the control of the management of the Company. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. You should not place undue reliance on these forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements referenced above. Forward-looking statements speak only as of the date on which such statements are made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events.

## Overview 1<sup>st</sup> Half-Year 2013/14




Reimund Pohl  
CEO

## Group Financials 1<sup>st</sup> Half-Year 2013/14



Helmut Fischer  
CFO


## Questions & Answers



## PHOENIX group continues to grow in a challenging environment and further improves its capital structure

- Net turnover and total operating performance have increased significantly while the pharma market in Europe has continued to shrink.
- Total income decreases due to intensified competition in several key markets and negative currency influences.
- PHOENIX group has again reduced its net debt compared to previous year.

### Negative trend in European pharma market continues\*




### Market growth in key markets\*\*:


- Germany: +3.0%
- France: -3.0%
- Italy: -1.1%
- UK: -2.4%
- Sweden: -2.5%
- Netherlands: -6.2%

\* Source: IMS Health Executive Market Report;  
\*\* half-year growth rate compounded from quarterly figures


# PHOENIX has differentiated itself from the negative market trend, but experiences pressure on margins



# Despite the higher level of turnover, operating expenses are only slightly above last year



# The challenging market situation leads to a reduction in operating profit and profit before tax



\* PY adjusted due to the first-time adoption of IAS 19R

## Group Financials 1<sup>st</sup> Half-Year 2013/14



Helmut Fischer  
CFO

## Questions & Answers



PHOENIX is able to grow in terms of net turnover, but the challenging market environment puts pressure on the results

Profit & Loss	1st HY 2012/13*		1st HY 2013/14		Delta	
	in m€	%	in m€	%	in m€	%
<b>Net turnover</b>	<b>10,518.8</b>	<b>100%</b>	<b>10,807.7</b>	<b>100%</b>	<b>288.9</b>	<b>2.7%</b>
Cost of goods sold	-9,437.8	-89.7%	-9,775.1	-90.4%	-337.4	3.6%
<b>Gross profit</b>	<b>1,081.1</b>	<b>10.3%</b>	<b>1,032.6</b>	<b>9.6%</b>	<b>-48.5</b>	<b>-4.5%</b>
Other operating income	74.2	0.7%	76.0	0.7%	1.8	2.5%
Personnel expenses	-535.3	-5.1%	-534.9	-4.9%	0.4	-0.1%
Other operative expenses	-345.2	-3.3%	-352.5	-3.3%	-7.2	2.1%
Result from associates and other invest.	1.7	0.0%	0.8	0.0%	-0.8	-50.6%
<b>EBITDA</b>	<b>276.4</b>	<b>2.6%</b>	<b>222.2</b>	<b>2.1%</b>	<b>-54.3</b>	<b>-19.6%</b>
Depreciations	-50.5	-0.5%	-53.3	-0.5%	-2.8	5.5%
Financial result	-81.9	-0.8%	-52.2	-0.5%	29.7	-36.2%
<b>Profit before tax</b>	<b>144.1</b>	<b>1.4%</b>	<b>116.7</b>	<b>1.1%</b>	<b>-27.4</b>	<b>-19.0%</b>
Income taxes total	-42.4	-0.4%	-37.7	-0.3%	4.8	-11.2%
<b>Profit for the period</b>	<b>101.7</b>	<b>1.0%</b>	<b>79.0</b>	<b>0.7%</b>	<b>-22.6</b>	<b>-22.3%</b>

## Developments

- **Net turnover** has significantly improved, mainly due to the good development in the German market, but also in other European markets
- Due to the competitive situation in several markets **gross profit** decreased
- Whereas **other operating income** and **personnel expenses** developed well, other **operative expenses** increased by one-time costs for the group-wide optimization initiative PHOENIX *FORWARD* and due to higher transport costs
- **Depreciations** slightly increased
- Also excluding the one-time effect of the dissolution of transaction costs (-18.4 m€) in the previous year, the **financial result** has improved by approx. +6 m€ thanks to the reduced net debt and better financing conditions and +5 m€ due to the sale of financial assets
- The **profit before tax** is lower than previous year due to the missing gross profit
- The **tax rate** is at 32.3% compared to 29.3% in the previous year, mainly due to volatility of the Estimated Effective Tax Rate (EETR) approach of IAS 34. At the end of the fiscal year a tax rate in the range of the previous year is expected

\* PY adjusted for reclassification of transport costs and due to the first-time adoption of IAS 19R

# PHOENIX group improves the financial result, once more

Financial result (in m€)	1st HY 2012/13**	1st HY 2013/14	Delta
Interest income	14.1	11.3	-2.8
Interest expenses	-78.3	-69.0	9.3
<b>Interest result</b>	<b>-64.2</b>	<b>-57.7</b>	<b>6.5</b>
Dissolution of transaction costs due to premature refinancing	-18.4	0.0	18.4
Other net financial result*	0.7	5.4	4.7
<b>Financial result</b>	<b>-81.9</b>	<b>-52.2</b>	<b>29.7</b>

## Developments

- Slight reduction of interest income
- Lower interest expenses are mainly driven by reduced debt and optimized interest rates
- Most influencing factor in the previous year was the premature refinancing of PHOENIX group, resulting in the dissolution of corresponding transaction costs
- Improvement in other net financial result due to the sale of financial assets


\* Other net financial result comprises

- “other financial income and expenses“,
- “financial income and expenses from derivatives” as well as
- “exchange rate gains and losses” related to the financial result

\*\* Prior year restated due to the first-time adoption of IAS 19R

# PHOENIX continues its committed path of strengthening its balance sheet

(m€)



## Developments


- Equity and equity ratio further improved by profit for the period
- Financial liabilities increased, including new bond (300 m€ placed in May 2013)
- Inventories increased due to higher turnover
- Trade receivables successfully decreased, but also payables decreased
- Moderate increase of absolute NWC (+37 m€ vs. YE 2012/13), measured in average NWC days, NWC is lower than year-end and previous year's 1<sup>st</sup> half-year:
  - NWC days HY 2012/13: 38.1
  - NWC days YE 2012/13: 37.5
  - NWC days HY 2013/14: 36.5

- Equity
- Other
- Net Working Capital
- Financial Liabilities
- Cash & Equivalents

Balance ratio

# Significant net debt improvement from the 1<sup>st</sup> HY 2012/13 to the 1<sup>st</sup> HY 2013/14

(m€)



### Developments


- Net debt reduction of 337 m€ achieved by significant funds from operations (cash flow before changes in working capital) and net working capital improvements
- Investments (mainly capex and pharmacy acquisitions) on a comparable level as in the previous year
- Slight increase in off-balance ABS/Factoring

# The new bond and the refinancing in Italy improve the maturity profile

## Financial facilities and headroom

(m€)

09/15/2013




- Diversified financing structure and significant financial headroom
- Reduced financing requirements allows reduction of credit lines: Reduction of the SFA term loan by 150 m€ and new SFA in Italy (400 m€ in place since 08/2013; 50 m€ of old SFA in place till 12/31/2013)

## Debt maturity profile

(m€)

09/15/2013



- The new bond (300 m€ till May 2020) and the new SFA Italy (400 m€ till 2016) significantly improve the maturity profile
- ABS/factoring extended to some parts


## Targets

- Refinancing the existing SFA in Italy with a volume of 750 m€, expiring 12/31/2013
- Securing the traditional low level of interest in Italy
- Adjustment of the credit volume to the optimized net working capital in Italy
- Continuing the good relationship with Italian banks in one of PHOENIX's largest markets

## Key Facts

- Volume: 400 m€
- Term: 3 years (08/2013 – 12/2016)
- Lenders: Syndicate of Italian banks

# The active management of net working capital shows significant improvements




## Key Achievements

- Slight increase in stock due to higher turnover
- Trade receivables decreased despite higher turnover
- Payables absolutely increased vs. previous year, day-wise slightly decreased
- Overall, significantly improved NWC

• Balance sheet figures as externally reported  
 • Net working capital days: Average figures for the respective period; figures including ABS/factoring; may include rounding differences

# Free cash flow development



## Cash flow development

- The cash flow before changes in working capital is lower due to the lower level of EBITDA
- Smaller negative swing in working capital compared to previous year, due to a better level of payables. Overall, normal seasonal development in working capital, with increase of working capital in the 1<sup>st</sup> half-year and decrease in the 2<sup>nd</sup> half-year
- Cash outflow from investing activities is slightly decreased due to lower investments in fixed assets and higher cash inflows from the disposal of fixed assets
- Compared to previous year's 1<sup>st</sup> half-year, the level of free cash flow has improved

\* Prior year restated due to the first-time adoption of IAS 19R




# Summary: Development of key credit indicators

	01/31/2013	07/31/2013	Delta
Equity (in m€)	2,103.8	2,177.9	3.5%
Equity ratio	28.7%	29.0%	+0.3pp
Net debt (in m€)	1,611.5	1,673.3	3.8%
Gearing (Net debt/equity)	76.6%	76.8%	+0.2pp
	1st HY 2012/13	1st HY 2013/14	Delta
EBITDA (in m€)	276.4	222.2	-19.6%
EBITDA-margin	2.6%	2.1%	-0.5pp
Adjusted EBITDA (in m€)	288.2	232.2	-19.5%
Adj.-EBITDA-margin	2.7%	2.1%	-0.6pp
Net debt / adjusted EBITDA (LTM)	3.46	3.21	-7.2%
Interest coverage ratio ** (EBIT / Interest Expenses*)	2.9	2.4	-15.1%
Profit before tax (in m€) **	144.1	116.7	-19.0%
PBT-margin **	1.4%	1.1%	-0.3pp
Profit after tax (in m€) **	101.7	79.0	-22.3%
PAT-margin **	1.0%	0.7%	-0.3pp

\* Interest expenses excluding fx-effects and other financial expenses

\*\* Prior year restated due to the first-time adoption of IAS 19R

# Developments of PHOENIX' bonds



Source: Bloomberg, 09/24/2013

# The outperformance of the 1<sup>st</sup> PHOENIX bond is shown by the spread to the iBoxx high-yield index



\*Yield to maturity minus swap rate  
Date 09/24/2013

## Key messages

- Continuously improve the capital structure by reducing the level of indebtedness
- Aim to further strengthen the equity ratio
- Maintain ratio of Net Debt to Adj. EBITDA of around 3.0x
- Long-term safeguarding of liquidity via well-balanced and diversified funding sources

## Liquidity & Risk management

- Centralized group funding – Financing of subsidiaries through intra-group loans, except for local ABS/Factoring programs and for the total Italian subgroup
- Centralized cash pooling structure within PHOENIX group
- Well-diversified corporate financing structure
- Financial derivatives only used for hedging purposes, not for speculation

## Growth strategy

- PHOENIX's growth strategy is focused on above market organic growth
- Profitable and financially sound add-on acquisitions may also be pursued, but only within a predefined acquisition budget

Our shareholder fully backs our financial policy

## Financial outlook of PHOENIX group for the fiscal year 2013/14:

---

- Generally, we do not expect the pharmaceutical markets in Europe to record any growth in the fiscal year 2013/14
- Despite this current period of market weakness, we expect revenue to increase in 2013/14, especially due to Germany, where we anticipate a tangible increase in revenue in 2013/14 after reporting a decline in 2012/13
- With regard to EBITDA, we expect a decline in 2013/14 compared to 2012/13, which cannot be compensated by the improved financial result
- Significant positive effects from the PHOENIX FORWARD program will most likely arise as of fiscal year 2014/15

---

Reporting Event	Date
Results of the 3 <sup>rd</sup> quarter 2013/14	Thursday, 12/19/2013



**PHOENIX** group